Literature DB >> 14605452

[Systemic chemotherapy for transitional cell carcinoma of the urothelium].

J Lehmann1, M Retz, M Hack, S Siemer, M Stöckle.   

Abstract

Moderate activity of systemic chemotherapy for advanced urothelial cancer has been reported for more than 30 years. Only with the advent of potent combination therapy in the mid eighties of the past century clinically significant response rates as well as prolonged survival has been documented. This review summarizes seven Phase-III trials of systemic chemotherapy for advanced urothelial carcinoma as well as results from adjuvant and neoadjuvant Phase-III trials for muscle-invasive bladder cancer including the most recent reports. Copyright 2003 S. Karger GmbH, Freiburg

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14605452     DOI： 10.1159/000074741

Source DB:  PubMed          Journal:  Onkologie        ISSN： 0378-584X


  2 in total

1.  ["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"].

Authors:  A Bannowsky; B Wefer; M Naumann; M Hamann; S Hautmann; K-P Jünemann
Journal:  Urologe A       Date:  2005-08       Impact factor: 0.639

2.  Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma.

Authors:  C Bolling; T Graefe; C Lübbing; F Jankevicius; S Uktveris; A Cesas; W-H Meyer-Moldenhauer; H Starkmann; M Weigel; K Burk; A-R Hanauske
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.